Selpercatinib Instructions

1. Indications and Usage

Selpercatinibis a kinase inhibitor used to treat:

1.Adult patients with locally advanced or metastatic non-small cell lung cancer(non-small cell lung cancer)Rearrangement during transfection(RET)Gene fusion detected by FDAapproved test.

2.Adult and pediatric patients aged 12 years and older with advanced or metastatic medullary thyroid carcinoma (MTC) have mutations identified by a U.S. Food and Drug Administration-approved test that require systemic therapy.

3.Adult and pediatric patients 12 years of age and older with advanced or metastatic thyroid cancer, as tested in an FDA-approved trial, patients requiring systemic therapy and patients refractory to radioactive iodine(if radioactive iodine is appropriate)

4.Adult patients with locally advanced or metastatic solid tumors have a genetic fusion that has progressed on or after prior systemic therapy, or for which there are no satisfactory alternative treatment options.

This indication received accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and characterization of clinical benefit in confirmatory trials.

2. Dosage and usage

Patients selected to receive serpatinibsubject to soft gene fusion(non-small cell lung cancer, thyroid or other solid tumors)or specific subcutaneous soft gene mutation(MTC)

1.The recommended dosage for adults and pediatric patients 12 and older is based on body weight:

50Under 50kg:120mg orally twice daily

50kg or more: 160mg orally twice daily

Reduce the dose of selpatinib in patients with severe hepatic impairment.

Three. Dosage form and strength

Capsule: 40mg, 80mg.

Four. Contraindications

No.

Five. Warnings and Precautions

1.Hepatotoxicity:StartSepretinib/SerpatinibBefore, before3< Monitor ALT and AST every 2 weeks every month, and then monthly as clinically indicated. Depending on severity, withhold, reduce dose, or permanently discontinue serpatinib.

2.Interstitial Lung Disease(ILD)/Pneumonia:Monitor for new or worsening pulmonary symptoms. Depending on severity, withhold, reduce dose, or permanently discontinue serpatinib.

3.Hypertension:Do not administer RETEVMO to patients with uncontrolled hypertension. Before starting retention, optimize blood pressure. Monitor blood pressure after 1 week, and thereafter at least monthly as clinically indicated. Depending on severity, withhold, reduce dose, or permanently discontinue serpatinib.

4.QTinterval prolongation:Monitor patients who are at significant risk for QTc prolongation. Assess QT interval, electrolytes, and TSH at baseline and periodically during treatment. Danretimol and strong, moderateThe QT interval should be monitored more frequently when coadministered with CYP3A inhibitors or drugs known to prolong the QTc interval. Based on severity, withhold, reduce dose, or permanently discontinue serpatinib.

5.Bleeding events: Patients with severe or life-threatening bleeding should permanently discontinue selepatinib/serpatinib.

6.Hypersensitivity:Discontinue indwelling and start corticosteroids. After resolution, continue reducing the dose and increasing it by 1 dose level per week until the dose before the allergy attack is reached. Steroids are continued until the patient reaches target dose and then tapered.

Tumor lysis syndrome:Monitor at-risk patients closely and treat as clinically indicated. (5.7)

7.Risk of impaired wound healing:Discontinue indwelling catheterization at least7 days before elective surgery. Do not administer this medication for at least 2 weeks after major surgery until the wound has completely healed. The safety of RETEVMO after resolution of wound healing complications has not been established.

8.Hypothyroidism:Monitor thyroid function before and regularly during treatment with Sepretinib/Selpatinib. Depending on severity, withhold medication until clinical stabilization or permanently discontinue.

9.Embryo-Fetal Toxicity:Can cause harm to the fetus. Inform women of reproductive potential of the potential risks to the fetus and use effective contraception.

6. Adverse reactions

The most common adverse reactions (≥25%)are edema, diarrhea, fatigue, dry mouth, hypertension, abdominal pain, constipation, rash, nausea and headache.

The most common Grade 3 or Grade 4 laboratory abnormalities(≥5%) are lymphopenia, alanine aminotransferase(ALT)Increased, aspartate aminotransferase(AST)increased, sodium decreased, and calcium decreased.

7. Drug interactions

Acid reducing agent:Avoid combined use. If coadministration cannot be avoided, retimol should be taken with food(with PPI) or change the timing of its administration (administered with H2 receptor antagonists or locally acting antacids).

Strong and ModerateCYP3AInhibitors:Avoid coadministration. If coadministration cannot be avoided, reduce remaining dosage. Strong and ModerateCYP3AInducers:Avoid coadministration.

CYP2C8andCYP3Asubstrates:Avoid coadministration. If coadministration cannot be avoided, modify the substrate dosage as recommended in their product labeling.

CertainP-gpSubstrates:Avoid coadministration. If coadministration cannot be avoided, modify the substrate dosage as recommended in their product labeling.

8. Use among specific groups of people

Lactation:It is recommended not to breastfeed.

Pediatric Use:Monitoring of open growth plates in adolescent patients. If abnormal conditions occur, consider interrupting or stopping recording.

Specifications of generic drug serpatinib40mg120 tablets4 more than a thousand. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0